breast cancer - search results
If you're not happy with the results, please do another search
A new study reveals an important and complex role for epithelial-mesenchymal transition (EMT) programs during triple-negative breast cancer (TNBC) metastasis.
The drug is the first approved therapy for patients with the newly identified HER2-low breast cancer subtype.
The study, which accrued enough patients for African Americans to comprise 31% of the cohort, found that there was no difference in the three-year overall survival rate or event-free survival rate by race.
Hormone replacement therapy is not generally associated with breast cancer reoccurrence, a new study shows.
Researchers from the Baylor College of Medicine have discovered a potentially more effective treatment for a specific type of HER2 mutant metastatic breast cancer.
Probiotic bacteria may enhance anti-cancer activities of the breast cancer drug tamoxifen and other endocrine-targeted therapies, which could help improve the treatment of ER+ breast cancer.
New biomarker-specific breast cancer subtypes for high-risk patients were revealed by the I-SPY 2 trial.
Enhertu demonstrated a 49% reduction in the risk of disease progression or death versus chemotherapy in patients with HER2-low metastatic breast cancer with hormone receptor-positive disease.
Metformin does not delay disease recurrence or death overall but may be effective in a subgroup of people with human epidermal growth factor receptor (HER)2-positive tumors.
Crown-like structures (CLSs) associated with the fat cells in HER2+ breast tumors could hinder the response of some patients to therapy, according to research from the University of Southampton.